High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

Abstract Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus, and it predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the least expensive treatment combination globally. In regional guidelines, longer treatment durations of SOF/DCV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2021-07, Vol.8 (7), p.ofab267-ofab267
Hauptverfasser: Flower, Barnaby, McCabe, Leanne, Le Ngoc, Chau, Le Manh, Hung, Le Thanh, Phuong, Dang Trong, Thuan, Vo Thi, Thu, Vu Thi Kim, Hang, Nguyen Tat, Thanh, Phan Thi Hong, Dao, Nguyen Thi Chau, An, Dinh Thi, Tan, Tran Thi Tuyet, Nga, Tarning, Joel, Kingsley, Cherry, Kestelyn, Evelyne, Pett, Sarah L, Thwaites, Guy, Nguyen Van, Vinh Chau, Smith, David, Barnes, Eleanor, Ansari, M Azim, Turner, Hugo, Rahman, Motiur, Walker, Ann Sarah, Day, Jeremy, Cooke, Graham S
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral agents
Care and treatment
Comparative analysis
Fibrosis
Genetic aspects
Hepatitis C virus
Liver
Liver cirrhosis
Major
Type 2 diabetes
World health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus, and it predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the least expensive treatment combination globally. In regional guidelines, longer treatment durations of SOF/DCV (24 weeks) are recommended for cirrhotic individuals, compared with other pangenotypic regimens (12 weeks), based on sparse data. Early on-treatment virological response may offer means of reducing length and cost of therapy in patients with liver fibrosis. Methods In this prospective trial in Vietnam, genotype 6-infected adults with advanced liver fibrosis or compensated cirrhosis were treated with SOF/DCV. Day 14 viral load was used to guide duration of therapy: participants with viral load
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab267